Grisaru-Tal, Sharon http://orcid.org/0000-0003-3530-308X
Rothenberg, Marc. E. http://orcid.org/0000-0001-9790-6332
Munitz, Ariel http://orcid.org/0000-0003-1626-3019
Funding for this research was provided by:
Israel Science Foundation (542/20)
United States-Israel Binational Science Foundation (2015163)
Israel Cancer Association
Israel Cancer Research Fund
TAU | Varda and Boaz Dotan Research Center for Hemato-Oncology Research, Tel Aviv University
Azrieli Foundation
Campaign Urging Research for Eosinophilic Disease
Article History
Received: 21 March 2022
Accepted: 18 July 2022
First Online: 24 August 2022
Competing interests
: A.M. is a consultant and/or international advisory board member for GSK, AstraZeneca, Sanofi, Oravax and Sartorious and is an inventor of patents owned by the Tel Aviv University. M.E.R. is a consultant for Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, Allakos, Celldex Therapeutics, Nextstone One, Bristol Myers Squibb, AstraZeneca, Ellodi Pharma, GSK, Regeneron/Sanofi, Revolo Biotherapeutics and Guidepoint; has an equity interest in the first seven companies listed and royalties from reslizumab (Teva Pharmaceuticals), PEESSv2 (Mapi Research Trust) and UpToDate; and is an inventor of patents owned by Cincinnati Children’s Hospital. S.G.-T. declares no competing interests.